Balt announced today it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin The Squid Trial for the Embolization of the Middle ...
Balt’s Squid liquid embolic receives US FDA approval for adjunctive treatment for chronic subdural hematomas: Boston Friday, February 6, 2026, 17:00 Hrs [IST] Balt Inc, a global ...
ARE INCLUDED. ' ’ITS NOT EVERYTHING WE ASKED ERWHE WE DID ASK FOR A LITTLE BIT MEOR IDENTIFYING INFORMATION. OUR COMMUNITY. NONPROFIT ORGANIZATION IS ASKING MORE QUESTIONS. BALTIMORE ACTION LEGAL TEAM ...
BOSTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the publication of The Squid Trial for the Embolization of the Middle ...
PARIS and MONTMORENCY, France, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Balt, a global medical device leader in interventional neuroradiology, announces that it has secured €355 million in financing from a ...
BOSTON, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Balt, Inc., a global technology leader in neurovascular devices, today announced the Premarket Approval (PMA) of the Squid™ liquid embolic agent. Squid is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results